Azficel-T

Azficel-T
Clinical data
Trade namesLaviv
AHFS/Drugs.comMicromedex Detailed Consumer Information
Routes of
administration		Intradermal
ATC code
  • None
Legal status
Legal status
Identifiers
DrugBank
UNII
KEGG

Azficel-T, sold under the brand name Laviv, is a cell therapy product used to treat moderate to severe nasolabial fold wrinkles (the lines running from the sides of the nose to the corners of the mouth) in adults.

The treatment is autologous, meaning it uses the patient’s own cells. Specifically, fibroblasts—cells involved in skin structure and repair—are extracted from a small skin sample, cultured in a laboratory to increase their number, and then re-injected into the patient’s skin to improve appearance.

Azficel-T was approved for medical use in the United States in June 2011.

References

  1. 1 2 "Laviv (Azficel-T)". U.S. Food and Drug Administration (FDA). 22 July 2017. Archived from the original on 16 December 2019. Retrieved 1 April 2020.
  2. 1 2 3 "Autologous Fibroblasts". U.S. Food and Drug Administration (FDA). 29 June 2017. Archived from the original on 22 July 2017. Retrieved 1 April 2020.

Further reading